Fig. 4
Mn2+ plus YM101 therapy prolonged survival and inhibited tumor metastasis. a–b The overall survival curves of EMT-6-bearing and B16-bearing mice receiving the treatment of combination therapies or monotherapies. BALB/c mice were challenged with 3 × 105 EMT-6 cells on day 0. Therapy was initiated on day 2 (8 mice for each group). The survival status of mice was monitored for 45 days. C57BL/6 mice were subcutaneously inoculated with 2 × 105 B16 cells on day 0. Treatment was started on day 1 (8 mice for each group). The survival status of mice was monitored for 4 weeks. c The representative images of lung tissues of mice receiving the treatment of combination therapies or monotherapies. C57BL/6 mice were intravenously injected with 2 × 105 B16 cells on day 0. Treatment was started on day 1 (8 mice for each group). 21 days after inoculation, the mice were euthanized, and the lung tissues were collected. d The number of B16 tumor nodules in lung tissues of mice receiving the treatment of combination therapies or monotherapies. e The weights of lung tissues of mice receiving the treatment of combination therapies or monotherapies. f The representative images of H&E staining of lung tissues of mice receiving the treatment of combination therapies or monotherapies. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to combination treatment